ALK and non-small cell lung carcinoma: Osimertinib overcomes alectinib resistance caused by increased amphiregulin (AREG) expression in the leptomeningeal carcinomatosis (LMC) model of ALK-rearranged lung cancer; AREG levels are also significantly higher in the cerebrospinal fluid of patients with alectinib-resistant ALK-rearranged NSCLC with LMC [50].